[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571846":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":19,"responsibleParty":34,"collaborators":19,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":19,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":19,"enrollmentInfo":45,"targetDuration":19,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":19,"overallStatus":55,"whyStopped":19,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":19},{"fullName":5,"class":6},"Ottawa Hospital Research Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Endoscopically placed lumen-apposing metal stents for the treatment of IBD-strictures","EXPERIMENTAL","Individuals will receive endoscopic lumen-apposing metal stents. The specific size of the stent used will depend on the length of the stricture. All LAMS placements are part of one arm.",[13],"Procedure: Endoscopically placed lumen-apposing metal stents for the treatment of IBD-strictures",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","We will apply standard procedures for endoluminal stenting. A therapeutic colonoscope will be advanced through the bowel up until the stricture. A guidewire will be passed through the lumen at the stricture site. LAMS will be used for strictures \\<6cm, with stents ranging in size from 10-16mm in diameter and up to 60mm in length. The stent will be deployed across the stricture with the assistance of endoscopic and fluoroscopic imaging. Individuals will undergo a repeat colonoscopy in 1-3 months to remove the stent.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Avijit Chatterjee, MD, MSc.","PRINCIPAL_INVESTIGATOR",[25,30],{"name":22,"role":26,"phone":27,"phoneExt":28,"email":29},"CONTACT","6137378899","79917","achatterjee@toh.ca",{"name":31,"role":26,"phone":27,"phoneExt":32,"email":33},"Brittany Haas, MSc.","73308","bhaas@ohri.ca",{"type":35,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100571846","endoscopically-placed-lumen-apposing-metal-stents-for-the-treatment-of-symptomatic-intestinal-strictures-in-individuals-with-inflammatory-bowel-disease-100571846",false,"NCT06725563","Endoscopically Placed Lumen-Apposing Metal Stents for the Treatment of Symptomatic Intestinal Strictures in Individuals With Inflammatory Bowel Disease","Endoscopically Placed Lumen-Apposing Metal Stents as a Safe Alternative to Surgery for the Treatment of Symptomatic Intestinal Strictures in Individuals With Inflammatory Bowel Disease","Inclusion Criteria:\n\n* ≥18 years of age\n* Established Diagnosis of inflammatory bowel disease\n* Symptomatic, single, fibrostenotic or anastomotic stricture \\<6 cm in length without severe active inflammation, pre-stenotic intestinal fistula or penetrating complication, and within reach of the adult colonoscope (colon or terminal ileum)\n* Ability to accurately gauge stricture length with imaging and safely deploy the stent using conventional fluoroscopic techniques\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* More than one intestinal stricture\n* Stricture out of reach of standard adult colonoscope\n* High-grade stricture (complete or near complete bowel obstruction\n* Severe active inflammation in the stricture or associated penetrating complication, including fistula, inflammatory phlegmon or abscess\n* Contraindications for endoscopic therapy, including:\n* Complete Bowel obstruction\n* Severe cardiorespiratory comorbidity\n* Unable to tolerate sedation or anesthesia\n* Non-reversible coagulopathy","ALL","18 Years",{"count":46,"type":47},20,"ESTIMATED","INTERVENTIONAL",[50],"NA","This is a single-center prospective pilot study in patients with symptomatic partially obstructing intestinal strictures without severe active inflammation or penetrating complications, evaluating the use of LAMS with respect to symptom and quality of life improvement and the development of stent-related complications.",[53,54],"Inflammatory Bowel Diseases","Stricture; Bowel","NOT_YET_RECRUITING","2024-12-04",{"date":58,"type":59},"2024-12-10","ACTUAL",{"date":61,"type":47},"2025-01-01",{"date":63,"type":47},"2026-12-31",{"name":5,"class":6}]